Vaxcyte (PCVX) Total Current Liabilities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Total Current Liabilities data on file, last reported at $242.1 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $242.1 million, up 149.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $242.1 million (up 149.58% YoY), and the FY2025 annual result was $205.8 million, up 46.78% from the prior year.
• Total Current Liabilities climbed to $242.1 million in Q1 2026 per PCVX's latest filing, from $205.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $242.1 million in Q1 2026 and troughed at $27.2 million in Q1 2022.
• A 5-year average of $106.7 million and a median of $87.1 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities sank 50.47% in 2022, then soared 258.64% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $40.5 million in 2022, then soared by 258.64% to $145.3 million in 2023, then dropped by 3.55% to $140.2 million in 2024, then soared by 46.78% to $205.8 million in 2025, then advanced by 17.66% to $242.1 million in 2026.
• Business Quant data shows PCVX's Total Current Liabilities at $242.1 million in Q1 2026, $205.8 million in Q4 2025, and $200.0 million in Q3 2025.